Larimar Therapeutics, Inc. (LRMR) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
LRMR currently has 104M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 70.87% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 14, 2026 |
10-Q filing | 103.9M shares outstanding |
100M | 0 |
| Mar 19, 2026 |
10-K filing | 103.9M shares outstanding |
100M | 0 |
| Nov 05, 2025 |
10-Q filing | 78.3M shares outstanding |
78M | 0 |
| Aug 14, 2025 |
10-Q filing | 85.6M shares outstanding |
86M | 0 |
| Apr 30, 2025 |
10-Q filing | 64.0M shares outstanding |
64M | 0 |
| Mar 24, 2025 |
10-K filing | 61.3M shares outstanding |
61M | 0 |
| Oct 30, 2024 |
10-Q filing | 63.8M shares outstanding |
64M | 0 |
| Aug 08, 2024 |
10-Q filing | 63.8M shares outstanding |
64M | 0 |
| May 09, 2024 |
S-3 filing: The company is filing an S-3 to offer and sell up to $300,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time. |
64M | 0 |
| May 09, 2024 |
10-Q filing | 63.8M shares outstanding |
64M | 0 |
| Mar 14, 2024 |
10-K filing | 63.8M shares outstanding |
64M | 0 |
| Nov 14, 2023 |
10-Q filing | 43.9M shares outstanding |
44M | 6.4M |
| Aug 10, 2023 |
10-Q filing | 43.9M shares outstanding |
44M | 6.4M |
| May 15, 2023 |
10-Q filing | 43.9M shares outstanding |
44M | 6.4M |
| Mar 14, 2023 |
10-K filing | 43.3M shares outstanding |
43M | 7.1M |
| Nov 10, 2022 |
S-3 filing: The company may offer and sell up to $200,000,000 in the aggregate of common stock, preferred stock, debt securities and subscription rights from time to time in one or more offerings. |
43M | 7.1M |
| Nov 10, 2022 |
10-Q filing | 43.3M shares outstanding |
43M | 7.1M |
| Aug 11, 2022 |
10-Q filing | 18.3M shares outstanding |
18M | 32M |
| May 12, 2022 |
10-Q filing | 18.3M shares outstanding |
18M | 32M |
| Mar 25, 2022 |
10-K filing | 17.2M shares outstanding |
17M | 33M |
| Nov 12, 2021 |
10-Q filing | 18.3M shares outstanding |
18M | 32M |
| Aug 12, 2021 |
10-Q filing | 16.0M shares outstanding |
16M | 34M |
| May 10, 2021 |
10-Q filing | 15.4M shares outstanding |
15M | 35M |
| Mar 04, 2021 |
10-K filing | 15.4M shares outstanding |
15M | 35M |
| Nov 12, 2020 |
10-Q filing | 15.4M shares outstanding |
15M | 35M |
| Aug 14, 2020 |
S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, and debt securities. |
15M | 35M |
| Aug 14, 2020 |
10-Q filing | 15.4M shares outstanding |
15M | 35M |
| Jun 26, 2020 |
S-3 filing: This S-3 filing is for the offering and resale of up to 12,860,272 shares of common stock by selling stockholders of Larimar Therapeutics, Inc. |
37M | 13M |
| May 07, 2020 |
10-Q filing | 37.5M shares outstanding |
37M | 0 |
| Mar 05, 2020 |
10-K filing | 37.5M shares outstanding |
37M | 0 |